OBJECTIVE: We report the long-term results of the SENTI-ENDO study evaluating the impact of @entity1600 ( @entity1600 ) biopsy on management and survival in @entity1 with early stages of @entity1204 ( @entity1204 ). METHODS: @entity1 with FIGO stage I-II @entity1204 underwent pelvic @entity1600 biopsy after cervical dual injection ( @entity1136 and patent blue) and systematic pelvic node dissection. This study is a secondary endpoint reporting the long-term @entity1349 ( @entity1349 ) and the impact of the @entity1600 procedure on adjuvant therapies. RESULTS: The median follow-up was 50months (range: 3-77months). Eighteen of the 125 @entity1 (14.4%) experienced a recurrence. The 50-monthrecurrence-free survival ( @entity1349 ) was 84.7% with no difference between @entity1 with and without detected @entity1600 (p=0.09). Among @entity1 with detected @entity1600 (111), no difference in @entity1349 was observed between those with and without positive @entity1600 (p=0.5). In the whole population, adjuvant therapy was performed in low-, intermediate- and high-risk groups in 31 of 64 @entity1 (48.4%), 28 of 37 @entity1 (75.7%) and 14 of 17 @entity1 (82.3%), respectively (p=0.0001). For the 111 @entity1 with detected @entity1600 , EBRT was performed in 27 of the 89 with negative @entity1600 and in 11 of the 14 with positive @entity1600 (p=0.001). Chemotherapy was performed more frequently in @entity1 with positive @entity1600 (6/12, 50%) than in @entity1 with negative @entity1600 (7/56, 12.5%) (p=0.009). CONCLUSIONS: Our results support the impact of @entity1600 biopsy on surgical management and indications for adjuvant therapies. Further studies are required to assess the clinical impact of the @entity1600 biopsy in early stage @entity1204 .

Sentinel node biopsy for the management of early stage XXXX : Long-term results of the SENTI-ENDO study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1136 :: ('MESH:D013667', 'Chemical') :: ['technetium'] @entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial cancer', 'EC'] @entity1600 :: ('MESH:D014388', 'Disease') :: ['sentinel lymph node', 'SLN'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['recurrence free survival', 'RFS']
@entity1204 :: (MESH:D016889,Disease) :: ['endometrial cancer']
